Skip to main content
. 2012 Dec 28;7(12):e50946. doi: 10.1371/journal.pone.0050946

Table 2. Meta-analysis of the subgroups based on clinic-pathological factors related to TAM density from the available published studies.

Cancer type Clinic-pathological factors Number of studies Number of total patients HR (95% CI) p-value Results Reference
Colon cancer
TNM Stage (I/II vs. III/IV) 2 619 0.71 (0.35, 1.45) 0.194 Indeterminate (15), (29)
T status (T1/T2 vs. T3/T4) 2 191 0.35 (0.13, 0.90) 0.246 Positive (12), (29)
Lymph node metastasis 2 370 0.72 (0.13, 4.06) 0.013 Indeterminate (12), (30)
Distant metastasis 3 530 0.72 (0.24, 2.11) 0.005 Indeterminate (12), (18), (30)
Histological grade (well/moderate vs. poor) 3 858 0.26 (0.06, 1.06) 0.005 Indeterminate (12), (15), (30)
Pathologic classification (mucinous vs. nonmucinous) 2 648 2.53 (1.35, 4.73) 0.675 Negative (15), (18)
Gastric cancer
TNM Stage (I/II vs. III/IV) 1 97 2.40 (0.98, 5.91) NR Indeterminate (31)
T status (T1/T2 vs. T3/T4) 1 97 1.36 (0.54, 3.46) NR Indeterminate (31)
Lymph node metastasis 2 149 0.39 (0.19, 0.80) 0.302 Positive (31), (32)
Distant metastasis 1 52 1.30 (0.40, 4.28) NR Indeterminate (32)
Histological grade (well/moderate vs. poor) 1 97 0.54 (0.22, 1.32) NR Indeterminate (31)
Liver cancer
TNM Stage (I/II vs. III/IV) 3 514 1.27 (0.84, 1.93) 0.702 Indeterminate (22), (24), (35)
Vascular invasion (absent vs. present) 3 514 1.38 (0.87, 2.21) 0.410 Indeterminate (22), (24), (35)
Tumor differentiation 2 409 1.08 (0.70, 1.66) 0.956 Indeterminate (24), (35)
Tumor size (≤5 vs. >5cm) 2 409 1.76 (1.19, 2.60) 0.329 Negative (24), (35)
Hepatitis history (No vs. Yes) 2 407 1.45 (0.80, 2.60) 0.456 Indeterminate (22), (24)
Liver cirrhosis (No vs. Yes) 3 514 1.18 (0.75, 1.88) 0.886 Indeterminate (22), (24), (35)
Fibrous capsule (absent vs. present) 3 514 0.83 (0.58, 1.19) 0.750 Indeterminate (22), (24), (35)
Esophagus cancer
T status (T1/T2 vs. T3/T4) 1 56 2.73 (0.70, 10.60) NR Indeterminate (9)
Lymph node metastasis 1 56 0.75 (0.21, 2.59) NR Indeterminate (9)
Lymphatic invasion (absent vs. present) 1 56 3.21 (0.81, 12.8) NR Indeterminate (9)
Venous invasion (absent vs. present) 1 56 6.22 (1.48, 26.1) NR Negative (9)
Intrahepatic cholangiocarcinoma
UICC stage (I/II vs. III/IV) 1 55 3.31 (0.71, 15.4) NR Indeterminate (38)
Histological grade (well/moderate vs. poor) 1 55 5.25 (0.93, 29.7) NR Indeterminate (38)
Lymph node metastasis 1 55 1.06 (0.19, 6.05) NR Indeterminate (38)
Vascular invasion (absent vs. present) 1 55 2.13 (0.34, 13.2) NR Indeterminate (38)
Tumor size (<4 vs. ≥4cm) 1 55 1.38 (0.39, 4.87) NR Indeterminate (38)
Breast cancer
TNM Stage (I/II vs. III/IV) 1 78 1.20 (1.14, 1.28) NR Negative (42)
Histological grade (I/II vs. III) 3 2077 3.42 (2.71, 4.30) 0.742 Negative (41), (42), (43)
Lymph node metastasis 3 2077 1.29 (1.04, 1.62) 0.604 Negative (41), (42), (43)
Tumor size (≤2 vs. >2cm) 3 2077 1.43 (1.14, 1.80) 0.963 Negative (41), (42), (43)
Vascular invasion (absent vs. present) 1 1902 1.74 (1.35, 2.23) NR Negative (43)
HER-2 status (negative vs. positive) 1 1902 2.59 (1.75, 3.85) NR Negative (43)
Endometrial cancer
FIGO stage (I/II vs. III/IV) 2 169 2.34 (0.36, 15.39) 0.021 Indeterminate (44), (45)
Lymph node metastasis 1 109 0.43 (0.12, 1.53) NR Indeterminate (45)
Myometrial invasion (negative vs. positive) 1 109 2.09 (0.65, 6.69) NR Indeterminate (45)
Histological grade (I/II vs. III) 2 169 4.34 (0.70, 27.08) 0.044 Indeterminate (44), (45)
Pathologic classification (Endometrioid vs.non-endometrioid) 1 109 1.37 (0.41, 4.62) NR Indeterminate (45)
Prostate cancer
T status (T1/T2 vs. T3/T4) 1 85 3.30 (1.56, 6.96) NR Indeterminate (48)
Distant metastasis 1 85 1.06 (0.25, 4.54) NR Indeterminate (48)
Cervical cancer
FIGO stage (I/II vs. III/IV) 2 97 0.68 (0.06, 8.26) 0.063 Indeterminate (51), (52)
Lymph node metastasis 1 24 1.75 (0.26, 11.7) NR Indeterminate (51)
Bladder cancer
TNM Stage (I/II vs. III/IV) 1 63 5.76 (1.76, 18.9) NR Negative (53)
T status (T1/T2 vs. T3/T4) 1 63 17.6 (4,34, 71.1) NR Negative (53)
Distant metastasis 1 63 12.4 (2.50, 61.0) NR Negative (53)
Vascular invasion (absent vs. present) 1 63 10.8 (1.26, 92.4) NR Negative (53)
Ovary cancer
TNM Stage (I/II vs. III/IV) 1 89 0.52 (0.35, 0.77) NR Positive (54)
Lymph node metastasis 1 89 0.14 (0.05, 0.35) NR Positive (54)
Tumor differentiation 1 89 0.79 (0.34, 1.83) NR Indeterminate (54)
Tumor size (≤5 vs. >5cm) 1 89 0.94 (0.41, 2.17) NR Indeterminate (54)
Histological type (serous vs. nonserous) 1 89 0.81 (0.34, 1.9) NR Indeterminate (54)
Lung cancer
Pathologic stage (I vs. II/III/IV 2 345 1.29 (0.24, 6.78) <0.001 Indeterminate (13), (60)
Tumor differentiation 1 170 5.80 (2.99, 11.2) NR Negative (60)
T status (T1/T2 vs. T3/T4) 1 170 2.70 (1.40, 5.21) NR Negative (60)
Lymph node metastasis 1 170 2.72 (1.27, 5.82) NR Negative (60)
Vessel invasion 1 170 3.24 (1.69, 6.24) NR Negative (60)
Oral squamous cell carcinoma
TNM Stage (I/II vs. III/IV) 2 220 2.53 (1.46, 4.38) 0.888 Negative (21), (62)
T status (T1/T2 vs. T3/T4) 2 220 2.33 (1.34, 4.03) 0.328 Negative (21), (62)
Lymph node metastasis 2 220 2.56 (1.46, 4.47) 0.528 Negative (21), (62)
Tumor differentiation 2 220 1.32 (0.68, 2.57) 0.294 Indeterminate (21), (62)
Thyroid cancer
TNM Stage (I/II vs. III/IV) 1 37 4.31 (0.42, 43.7) NR Indeterminate (64)
Distant metastasis 1 37 4.17 (0.66, 26.1) NR Indeterminate (64)